Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account

Rep. Laura Friedman disclosed a stock exchange transaction, swapping Exact Sciences (EXAS) shares for Abbott Laboratories (ABT) through Fidelity in a trade valued at $1,001-$15,000. The move was tied to a merger and does not indicate an IPO or broader market signal. Abbott is noted at $95.90, near its 52-week low of $93.92, but the article provides no new company-specific catalyst.

Analysis

ABT is the cleaner beneficiary here, but the real signal is not the headline trade itself—it’s that capital is rotating into a lower-volatility healthcare compounder while the broader market is still discounting defensives as full. Near-term, the setup favors a re-rating if investors continue to pay up for earnings durability and balance-sheet resilience, especially when large-cap medtech and diagnostics are getting pressured by slower procedural volumes elsewhere in healthcare.

The second-order effect is on relative value within healthcare: ABT’s mix of diagnostics, devices, and nutrition gives it more ways to absorb macro noise than a pure-play diagnostics name like EXAS. That matters if reimbursement or test-volume growth softens; capital tends to migrate toward “good enough growth + pricing power,” and ABT is positioned to capture that flow. If the market starts rewarding quality over optionality, peers with higher execution risk and less diversified revenue will likely underperform on a 1-3 month horizon.

The contrarian view is that the trade is too small and too passive to be a true signal; the merger-related mechanics suggest no informed conviction. That means the opportunity is less about following the transaction and more about exploiting complacency in a stock sitting near cycle lows with limited downside unless earnings guide materially lower. The main reversal trigger is a sudden improvement in risk appetite that rotates money out of defensives into higher-beta healthcare and cyclicals, which would likely cap near-term multiple expansion.

Key Decisions for Investors

• Go long ABT vs. short EXAS on a 1-3 month horizon as a relative-value hedge: ABT offers lower idiosyncratic risk and better downside capture if healthcare multiples compress.
• Initiate a tactical long ABT call spread 3-6 months out to express a rebound toward fair value with defined risk; best if you expect a slow grind higher rather than a sharp rerating.
• Use ABT as a defensive healthcare anchor in a market-neutral basket long quality healthcare / short higher-variance diagnostics, targeting 5-8% relative outperformance if macro volatility rises.
• Avoid chasing EXAS on merger optics alone; if you want biotech/diagnostics exposure, wait for post-conversion selling pressure to clear before reassessing entry.
• If ABT breaks the recent low after earnings or guidance, cut quickly—this is a sentiment trade, and the thesis weakens if the market starts pricing in a slower 2025 growth profile.